What We're Reading: Page
Industry reads hand-picked by our editors
Apr 21, 2016
-
Wall Street Journal
Glaxo Investors Want CEO Who Can Revitalize R&D
-
FierceBiotech
With Sarepta’s fate uncertain, BioMarin CEO Bienaimé weighs the future of Duchenne drug
-
Channel NewsAsia
HSA fast-tracking dengue vaccine evaluation
-
Reuters
Alere shares sink after Abbott CEO fuels speculation deal at risk
Apr 20, 2016
Apr 19, 2016
Apr 18, 2016
Apr 15, 2016
-
Reuters
WHO group backs Sanofi's vaccine in areas with high dengue rates
-
Bloomberg
Bill Miller Buys Valeant Stock on Bet It Could Double
-
FierceBiotech
Bristol-Myers expands I/O hub, may hire up to 150 more for discovery team
-
Renaissance Capital
No IPO in sight: GenSight Biologics withdraws $65 million IPO
Apr 14, 2016
Apr 13, 2016
-
Wall Street Journal
Horizon Pharma Shares Tumble on Projected Earnings Details
-
The Street
Anavex Plays the Orphan Drug Stock Promotion Game
-
FierceBiotech
Baylor scientists ID dendritic cells as new cancer therapy targets
-
Food Dive
How medical foods offer growth opportunities for Nestle, packaged foods industry
Previous
